Workflow
Inovio Pharmaceuticals(INO)
icon
Search documents
Inovio Pharmaceuticals(INO) - 2024 Q1 - Earnings Call Presentation
2024-05-13 22:16
| --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------| | | | | | as throat cancer | | | | Occurs in the base of the tongue, tonsils and/or soft palate | | | | Typically causally related to high-risk subtypes of HPV, some cases are carcinogen-driven | | | | HPV+ throat cancer rapidly increasing in incidence | | | | among patients in high-income countries ◦ Surpassed cervical ...
Inovio Pharmaceuticals(INO) - 2024 Q1 - Quarterly Results
2024-05-13 20:10
Exhibit 99.1 • The proposed confirmatory trial will be randomized and placebo-controlled, involving approximately 100 patients with a history of ≥2 surgeries per year, with a treatment option for the placebo arm at trial end. This trial design is intended to target a broader spectrum of RRP disease than other candidates currently in development. If INO-3107 receives full approval from the FDA, INOVIO believes the design of the confirmatory trial could also support expansion into global markets based on feed ...
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
Prnewswire· 2024-05-13 20:05
PLYMOUTH MEETING, Pa., May 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2024 and provided an update on recent company developments. "In the first quarter of 2024, we continued to deliver on our priorities for the year. Of utmost importance, we remain on track to submit our B ...
Inovio Pharmaceuticals(INO) - 2024 Q1 - Quarterly Report
2024-05-13 20:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction of ...
INOVIO to Participate in Upcoming Investor Conferences in May
Prnewswire· 2024-04-29 12:00
PLYMOUTH MEETING, Pa., April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that management will participate in the following investor conferences during the month of May: The Citizens JMP Life Sciences ConferenceDate: Tuesday, May 14, 2024Time: 11:30 AM ETPresenter: Dr. Jacqueline Shea, President & CEOFormat: Fireside Ch ...
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Prnewswire· 2024-04-15 22:39
PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 ...
Inovio Pharmaceuticals(INO) - 2023 Q4 - Annual Report
2024-03-06 21:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) (State or other jurisdiction of incorporation or organiza ...
Inovio Pharmaceuticals(INO) - 2023 Q3 - Earnings Call Presentation
2023-11-10 04:11
Precancerous Anal Dysplasia: Phase 2 open-label trial n=24 3 or 4 dose regimen at Months 0, 1, 3 and Week 36 (optional) Final findings (6 months after start of treatment) Clearance of HPV 16/18+ lesions: 50% of patients The Spontaneous Rate is estimated to be less than 27% • VGX-3100: composed of plasmids encoding for HPV-16 and HPV-18 subtypes; E6 and E7 oncogenes • Open-label trial of VGX-3100 in 24 HIV-negative participants with HPV-16 and/or -18-positive anal HSIL • 50% (11/22 evaluable) of participants ...
Inovio Pharmaceuticals(INO) - 2023 Q3 - Quarterly Report
2023-11-09 21:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-14888 INOVIO PHARMACEUTICALS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 33-0969592 (State or other jurisdiction ...
Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 25th Annual Global Investment Conference (Transcript)
2023-09-12 22:09
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Participants Jacqueline Shea - President and Chief Executive Officer Conference Call Participants Li Chen - H.C. Wainwright Li Chen Good afternoon, everyone, and welcome to H.C. Wainwright 25th Annual Global Investment Conference. My name is Li Chen, and I'm H.C. Wainwright Equity Research Associate. I'd like now to welcome our next speaker, Dr. Jacqueline Shea, Presi ...